Navigation Links
Fast Track Total Hip Replacement Surgery Is Effective and Safe

NEW YORK, July 1, 2011 /PRNewswire/ -- Generally healthy patients who undergo total hip replacement (THR) can be fast tracked to be discharged in two days compared with the standard three to six days, according to a new study by researchers at Hospital for Special Surgery (HSS) in New York City. The study could help cut down on hospital-acquired infections, reduce hospital costs and improve patient satisfaction.

"Before this study, we were uncertain how safe it would be to discharge patients within two days after a total hip replacement, but based on this study, we now know that it is safe. This is evidenced by the fact that the patients who were discharged within two days did not have an increase in complications, readmissions or reoperations," said Lawrence Gulotta, M.D., an orthopedic surgeon at HSS and first author of the study. "This is something that can help improve health care costs and provide better care for our patients by keeping them out of the hospital." Bryan Nestor, M.D., an orthopedic surgeon in Adult Reconstruction and Joint Replacement Service at HSS, was principal investigator of the study.

The prospective study that will be reported in an upcoming issue of  Springer's HSS Journal compared outcomes of patients undergoing THR at HSS between 2004 and 2008. One cohort of 149 patients underwent THR with a fast track protocol. The other cohort of 134 patients underwent THR followed by the hospital's traditional clinical pathway, which aimed to discharge patients at four days at that time.

Patients in the two cohorts were matched for age, sex, body mass index, and comorbidities. Patients were excluded if they had inflammatory arthritis, complex THR, and medical comorbidities such as a history of a myocardial infarction, pulmonary embolism or deep vein thrombosis. Blood clots can be a complication of THR, and patients with a history of these comorbidities cannot be treated with simple aspirin consumption. All patients in the study were discharged with aspirin.

Patients on the fast track protocol had a physical therapy session on the day of their surgery. The main difference was that a patient's pain medication was discontinued in the fast track cohort postoperative day one (as long as pain was deemed to be under control), whereas in the traditional cohort, pain medication is usually discontinued on day two.

Patients in both cohorts were sent home with aspirin, an arrangement for work with a physical therapist, a patient management plan including a list of daily goals, and nausea and pain control plans. A study coordinator screened for complications one day and one week after discharge.

The investigators found that 58 percent of the fast track cohort was discharged within two days of a THR and 73 percent were discharged within three days. The average discharge time was 2.6 days in the fast track cohort and 4.1 in the traditional cohort. Patients were less likely to be discharged rapidly in the fast track cohort, if they had significant post-operative pain, nausea, or dizziness. At one year, there were no differences in complications, readmissions or reoperation in the two cohorts.

"For a select group of patients, we have shown that a two day discharge is safe and feasible for patients undergoing a total hip replacement," Dr. Nestor said. He pointed out that the two day fast track is not for higher risk patients, the ones who were excluded from the study. While the authors did not measure if the fast track protocol saves money, since it involves shortened hospital stays, the researchers expect it to.

Roughly half a million THRs are conducted every year in the United States, and this number is expected to grow. Many in the baby boomer generation are not willing to be sedentary and as their joints age, they are demanding joint replacement surgeries to keep active.

Other HSS authors involved in the study are Douglas Padgett, M.D., Thomas Sculco, M.D., Michael Urban, M.D., Ph.D., and Stephen Lyman, Ph.D. No author received financial support related to the study.

About Hospital for Special Surgery

Founded in 1863, Hospital for Special Surgery (HSS) is a world leader in orthopedics, rheumatology and rehabilitation. HSS is nationally ranked No. 1 in orthopedics, No. 3 in rheumatology, No. 16 in neurology and No. 18 in geriatrics by U.S. News & World Report (2011-12), has received Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center, and has one of the lowest infection rates in the country. From 2007 to 2011, HSS has been a recipient of the HealthGrades Joint Replacement Excellence Award. A member of the NewYork-Presbyterian Healthcare System and an affiliate of Weill Cornell Medical College, HSS provides orthopedic and rheumatologic patient care at NewYork-Presbyterian Hospital at New York Weill Cornell Medical Center. All Hospital for Special Surgery medical staff are on the faculty of Weill Cornell Medical College. The hospital's research division is internationally recognized as a leader in the investigation of musculoskeletal and autoimmune diseases. Hospital for Special Surgery is located in New York City and online at

This news release was issued on behalf of Newswise(TM). For more information, visit

SOURCE Hospital for Special Surgery
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. Promising Cystic Fibrosis Compound on Track for Development
3. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
4. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
5. Chinese SFDA Grants Immtech Fast Track Status
6. R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
7. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
8. Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma
9. ImpactRx Tracks Decline in Zetia and Vytorin Prescribing
10. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
11. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
Post Your Comments:
(Date:12/2/2015)... 2015 TB Alliance and its partners ... medicines in the correct doses. The improved treatments ... set by the World Health Organization (WHO) in ... administer and affordable. The availability of these products ... by UNITAID. ...
(Date:12/1/2015)... and VANCOUVER , Dec. 1, 2015 ... OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today ... on the pre-planned interim futility analysis of the intent-to-treat ... safety issues were identified by the DMC. Both the ... final results are expected in the second half of ...
(Date:12/1/2015)... 01, 2015 ... the "Spinal Muscular Atrophy Market - ... 2015 - 2023" report to their ... announced the addition of the "Spinal ... Growth, Trends, and Forecast 2015 - 2023" ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... According to an article published on ... claim against the U.S. Department of Health and Human Services, claiming that any states ... are breaking the clause in the law prohibiting the denial of coverage for pre-existing ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... there are professionals who believe that with innovative technologies and under the right ... patient to get the benefit of a dual-approach to his or her therapeutic ...
(Date:12/1/2015)... ... December 01, 2015 , ... It’s official: Tattoo taboo ... — a number even greater among Millennials (a whopping one in three aged 18 ... more people who are dissatisfied with their ink. In fact, RealSelf , the ...
(Date:12/1/2015)... ... December 01, 2015 , ... For the ... is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic ... the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President North America. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic ... addition to the devices for sale in the United States. Clarity is a ... 1064 nm Nd:YAG lasers, into a single platform that is easy to own and ...
Breaking Medicine News(10 mins):